StockpollyBeta
Get App
Popularity #2,453
SLN · NASDAQ · Biotechnology

Silence Therapeutics (ADR) (SLN)

Develops liver-targeted siRNA medicines through its mRNAi GOLD platform.

$12.29
After hours0.00 (0.00%)
At close$12.29(+0.33%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue32161124000000
Cost of revenue213332000000
Gross profit1113−2−223000000
141418162126373326121513
Research & development91012111520272421988
5475651076475
General & administrative5475651076475
Other expenses000000020000
Operating income−13−13−6−18−23−3−37−33−26−12−15−13
2−241−8270−55101
Interest income201111000000
Interest expense01009−12000000
Other non-operating income−22−2−1−1−100−2−5−100
Income before tax−11−15−2−17−3024−37−38−21−12−15−12
Income tax expense−2−10−2−310000000
Net income from continuing operations−8−14−2−16−2714−37−38−21−12−15−12
Net income−8−14−2−16−2714−37−38−21−12−15−12
EPS, basic−$0.66−$1.08−$0.16−$0.99−$1.71$0.90−$2.34−$2.40−$1.32−$0.75−$0.96−$0.78
EPS, diluted−$0.66−$1.08−$0.16−$0.99−$1.71$0.90−$2.34−$2.40−$1.32−$0.75−$0.96−$0.78
Weighted average shares, basic121315161616161616161616
Weighted average shares, diluted121315161616161616161616
EBITDA−11−15−3−17−217−37−31−21−12−15−13
Depreciation & amortization000000000000
EBIT−11−15−3−17−227−37−31−21−12−15−13